GRI Bio, Inc.
Close on Oct 19, 2026
- Market cap
- $2.62M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q1 FY2026 Ended Mar 31, 2026 | May 14, 2026 | Before market open | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 4, 2026 | Before market open | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 15, 2025 | Before market open | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 17, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | During market hours | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 14, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | Apr 1, 2024 | Before market open | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 15, 2023 | Before market open | – | – | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 14, 2023 | Before market open | – | – | – |
| Q4 FY2022 Ended Dec 31, 2022 | Feb 24, 2023 | Before market open | – | – | – |
| Q3 FY2022 Ended Sep 30, 2022 | Nov 3, 2022 | During market hours | – | – | – |
| Q2 FY2022 Ended Jun 30, 2022 | Jul 28, 2022 | Before market open | – | – | – |
Press releases
Announcements GRI Bio filed with the SEC
A New Approach to Inflammatory Diseases NASDAQ: GRI | gribio.com CORPORATE PRESENTATION SEPT 2026 Exhibit 99.1
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic Pillars
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis
Other events · EX-99.1 to Form 8-K
GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline
Results of operations · Other events · EX-99.1 to Form 8-K
GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights
Results of operations · EX-99.1 to Form 8-K
GRI Bio Announces Reverse Stock Split
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
2223 Avenida de la Playa, #208
Other events · EX-99.1 to Form 8-K
GRI Bio Announces Closing of $8.0 Million Public Offering
Other events · EX-99.1 to Form 8-K
GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
Other events · EX-99.1 to Form 8-K
A New Approach to Inflammatory Diseases NASDAQ: GRI | gribio.com August 2025 Corporate Presentation Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
GRI Bio Reports 6-Week Interim Biomarker Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
Other events · EX-99.1 to Form 8-K
GRI Bio’s GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
Regulation FD disclosure · EX-99.1 to Form 8-K
GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025
Results of operations · EX-99.1 to Form 8-K
GRI Bio Announces Pricing of $5.0 Million Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
GRI Bio Regains Compliance with Nasdaq's Minimum Bid Price Rule
Listing notice · Other events · EX-99.1 to Form 8-K
GRI Bio Announces Reverse Stock Split
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024
Other events · EX-99.1 to Form 8-K
GRI Bio Announces Exercise of Warrants
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
GRI Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
A New Approach to Inflammatory Diseases NASDAQ: GRI | gribio.com August 2024 Corporate Presentation
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
GRI Bio Regains Compliance with Nasdaq
Listing notice · Other events · EX-99.1 to Form 8-K
GRI Bio Announces Pricing of $4.0 Million Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
GRI Bio Announces Reverse Stock Split
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
A New Approach to Inflammatory Diseases NASDAQ: GRI | gribio.com May 2024 Corporate Presentation
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
GRI Bio Announces Pricing of $5.5 Million Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
GRI Bio Announces Reverse Stock Split
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
A New Approach to Inflammatory Diseases NASDAQ: GRI | gribio.com January 2024 Corporate Presentation
Regulation FD disclosure · EX-99.1 to Form 8-K
GRI Bio (NASDAQ: GRI) Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
A New Approach to Inflammatory Diseases NASDAQ: GRI | gribio.com August 2023 Corporate Presentation Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
GRI Bio Enters into Asset Purchase Agreement with Aardvark Therapeutics, Inc. for the Sale of Legacy Asset, ADAIR
Material agreement · Acquisition or disposition completed · Other events · EX-99.1 to Form 8-K
GRI Bio (NASDAQ: GRI) Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor New to the Street Event
Other events · EX-99.1 to Form 8-K